Actively Recruiting
Atacicept in Multiple Glomerular Diseases
Led by Vera Therapeutics, Inc. · Updated on 2026-01-20
200
Participants Needed
1
Research Sites
121 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety and tolerability of atacicept in adult and adolescent participants and to measure the effect in reducing proteinuria and preserving renal function.
CONDITIONS
Official Title
Atacicept in Multiple Glomerular Diseases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Weight of at least 40 kg
- On a stable prescribed standard of care treatment according to local guidelines
- Systolic blood pressure 64 160 mmHg and diastolic blood pressure 64 90 mmHg at screening
- For participants aged 10 to under 18 years, average of 3 separate blood pressure readings below 95th percentile for age, gender, and height
- Diagnosis of IgAN, IgAVN, pMN, MCD, FSGS, or primary nephrotic syndrome
- For IgAN cohorts: age 64 10 years, biopsy proven IgAN or IgAVN, UPCR 64 0.5 g/g, eGFR 64 20 mL/min/1.73m2
- For pMN cohorts: age 64 18 years, biopsy-proven pMN, anti PLA2R antibodies 64 25 RU/mL, UPCR 64 1.5 g/g, low risk for spontaneous remission
- For nephrotic syndrome cohorts (MCD, FSGS, or pediatric idiopathic nephrotic syndrome): age 64 10 years, eGFR 64 30 mL/min/1.73m2, biopsy diagnosis of primary MCD or FSGS (adults) or challenging clinical course with steroids in children, UPCR 64 1.0 g/g, evidence of anti-nephrin antibodies
You will not qualify if you...
- Evidence of rapidly progressive glomerulonephritis with loss of 64 50% of eGFR within 3 months prior to and at screening
- Active viral or bacterial infections
- Existing conditions or clinically significant laboratory abnormalities interfering with study participation
- Receipt of live or live-attenuated vaccines within 30 days prior to enrollment
- Known hypersensitivity to atacicept or its components
- Additional criteria apply to each cohort or disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Vera Therapeutics
Brisbane, California, United States, 94005
Actively Recruiting
Research Team
V
Vera Therapeutics, Inc. Clinical Trials Information
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here